Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer

2016 ◽  
Vol 31 (2) ◽  
pp. 506-512 ◽  
Author(s):  
Kwang Hyun Chung ◽  
Ji Kon Ryu ◽  
Ban Seok Lee ◽  
Dong Kee Jang ◽  
Sang Hyub Lee ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Advanced Pancreatic Cancer ◽  
Carbohydrate Antigen ◽  
Favorable Outcome ◽  
Serum Carbohydrate Antigen

Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer

2017 ◽  
Vol 49 (4) ◽  
pp. 481-486 ◽  
Author(s):  
Pedro L. S. Usón Junior ◽  
Donato Callegaro-Filho ◽  
Diogo D. G. Bugano ◽  
Fernando Moura ◽  
Fernando C. Maluf
Keyword(s):  
Pancreatic Cancer ◽  
Predictive Value ◽  
Advanced Pancreatic Cancer ◽  
Carbohydrate Antigen ◽  
Early Mortality ◽  
Serum Carbohydrate Antigen

scholarly journals Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer

ESMO Open ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. e000668 ◽  
Author(s):  
Vincent Picozzi ◽  
Adnan Alseidi ◽  
Jordan Winter ◽  
Michael Pishvaian ◽  
Kabir Mody ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Carbohydrate Antigen ◽  
Tissue Growth ◽  
Locally Advanced Pancreatic Cancer ◽  
Complication Rates ◽  
Surgical Exploration ◽  
Matrix Deposition

PurposePancreatic ductal adenocarcinomas exhibit a high degree of desmoplasia due to extensive extracellular matrix deposition. Encasement of mesenteric vessels by stroma in locally advanced pancreatic cancer (LAPC) prevents surgical resection. This study sought to determine if the addition of a monoclonal antibody to connective tissue growth factor, pamrevlumab, to neoadjuvant chemotherapy would be safe and lead to improved resectability in this surgically adverse patient population.MethodsIn this phase I/II trial, 37 patients with LAPC were randomised 2:1 to gemcitabine/nab-paclitaxel plus (Arm A, n=24) or minus (Arm B, n=13) pamrevlumab. Those who completed six cycles of treatment were assessed for surgical eligibility by protocol-defined criteria. Resection rates, progression-free and overall survival were evaluated.ResultsEighteen (75%) patients in Arm A and seven (54%) in Arm B completed six cycles of therapy with similar toxicity patterns. In Arms A and B, carbohydrate antigen 19–9 response, as defined by ≥50% decline from baseline, occurred in 13 (65%) and 5 (42%), respectively. Sixteen (16%) per cent of patients were radiographically downstaged by National Comprehensive Cancer Network criteria (5 in Arm A (21%) and 1 (8%) in Arm B). Positron emission tomography normalised in 9 (38%) vs 3 (23%) of patients in Arm A vs Arm B, respectively, and correlated with surgical exploration. Eligibility for surgical exploration was 17 (71%) vs 2 (15%) (p=0.0019) and resection was achieved in 8 (33%) vs 1 (8%) of patients in Arm A vs Arm B (p=0.1193), respectively. Postoperative complication rates were not different between arms.ConclusionsNeoadjuvant chemotherapy with pamrevlumab holds promise for enhancing resection rates in patients with LAPC without added toxicity. This combination merits evaluation in a larger patient cohort.

The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients

Surgery Today ◽  
2013 ◽  
Vol 44 (9) ◽  
pp. 1692-1701 ◽  
Author(s):  
Mitsuro Kanda ◽  
Tsutomu Fujii ◽  
Hideki Takami ◽  
Masaya Suenaga ◽  
Yoshikuni Inokawa ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Carbohydrate Antigen ◽  
Accurate Predictor ◽  
Serum Carbohydrate Antigen

scholarly journals Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy

Cancer ◽  
2012 ◽  
Vol 119 (2) ◽  
pp. 285-292 ◽  
Author(s):  
Todd M. Bauer ◽  
Bassel F. El-Rayes ◽  
Xiaobai Li ◽  
Nazik Hammad ◽  
Philip A. Philip ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Advanced Pancreatic Cancer ◽  
Predictive Biomarker ◽  
Carbohydrate Antigen

Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer

Tumor Biology ◽  
2014 ◽  
Vol 35 (6) ◽  
pp. 5281-5286 ◽  
Author(s):  
Xueyan Li ◽  
Xiaozhong Guo ◽  
Hongyu Li ◽  
Hao Lin ◽  
Yingwei Sun
Keyword(s):  
Pancreatic Cancer ◽  
Carbohydrate Antigen ◽  
Serum Carbohydrate Antigen
Sign in / Sign up

Export Citation Format

Share Document